A. Oliver Sartor, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Noria Therapeutics Inc.
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Jannsen
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Isotopen Technologien Meunchen
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Fusion
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Denedron
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Constellation
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Clarity Pharmaceuticals
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Jannsen
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Noxopharm
    Date added:
    Date updated:
    09/19/2022

Pages

Return to Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2021)